Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of danusertib (PHA-739358) 24-hour IV infusion every 14 days in advanced/metastatic solid tumors
2006-003772-35Phase 2Completed
- Sponsor
- Nerviano Medical Sciences
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danusertib in breast cancer, ovarian cancer, colorectal cancer (CRC) and 4 more, sponsored by Nerviano Medical Sciences. Primary endpoint: Progression-free rate at 4 months. Started Mar 2007; status: completed.
02
Drugs
danusertib
03
Conditions
breast cancerovarian cancercolorectal cancer (CRC)pancreatic cancer (PC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-003772-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003772-35.